Brief: Ligand Pharmaceuticals Q2 EPS USD 0.13
08/08/2023 21:01
Aug 08 (Reuters) - Ligand Pharmaceuticals Q2 pretax profit USD 3.171 million. * Q2 basic EPS USD 0.13 * Q2 net income continuing operations USD 2.29 million * outlook FY revenue USD 124-128 million
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan